Patrick Kee, MD
Cardiovascular Disease · Humble, TXNPI 1881600815
Payments from drug & device makers
Across 70 payments — averaging $202.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$12K
- Cvrx, Inc.$356
- E.r. Squibb & Sons, L.L.C.$268
- Kestra Medical Technology Services, Inc.$222
- Heartflow, Inc.$205
- W. L. Gore & Associates, Inc.$192
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$10,73576%
- Travel & lodging$50%
- Food & beverage$3,40624%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 22 | $11,843 |
| Cvrx, Inc. | 3 | $356 |
| E.r. Squibb & Sons, L.L.C. | 8 | $268 |
| Kestra Medical Technology Services, Inc. | 3 | $222 |
| Heartflow, Inc. | 3 | $205 |
| W. L. Gore & Associates, Inc. | 1 | $192 |
| Lantheus Medical Imaging, Inc. | 5 | $167 |
| Regeneron Healthcare Solutions, Inc. | 3 | $160 |
| Novo Nordisk | 3 | $105 |
| Canon Medical Systems USA, Inc. | 3 | $99 |
| Abbott | 1 | $92 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $81 |
| Medtronic | 3 | $71 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $49 |
| Boston Scientific | 1 | $44 |
| Mindray DS USA, Inc. | 2 | $43 |
| Novartis | 1 | $34 |
| Edwards Lifesciences | 1 | $32 |
| Regeneron | 1 | $27 |
| Angiodynamics, Inc. | 1 | $16 |
| GE HealthCare | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$11,321
- Barostim Neo System$329
- GORE CARDIOFORM Septal Occluder$192
- EVKEEZA$121
- FFRct$115
- Assure WCD$109
How this compares
$14,146 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $30,392 |
| Dofetilide | 14 | $2,787 |
| Metoprolol Succinate | 44 | $620 |
| Chlorthalidone | 22 | $537 |
| Atorvastatin Calcium | 46 | $522 |
| Rosuvastatin Calcium | 28 | $315 |
| Ezetimibe | 23 | $302 |
| Carvedilol | 26 | $278 |
| Losartan Potassium | 21 | $270 |
| Spironolactone | 18 | $223 |
| Amlodipine Besylate | 23 | $158 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 18 | $154 |
| Lisinopril | 15 | $134 |
| Nifedipine ErNifedipine | 11 | $103 |
| Furosemide | 12 | $44 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Humble
- Raymond LittleHumble$445K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.